NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
1. NKGen acquires 65% stake in NKMax, overcoming financial challenges. 2. Transaction valued at approximately $16.9 million, enhancing global manufacturing control. 3. Acquisition expected to stimulate investor interest and accelerate NKGen's clinical development. 4. NKGen's lead therapy, troculeucel, shows promise with fast track designation from FDA. 5. Integration of NKMax boosts NKGen's independence and long-term growth potential.